BRAF and cutaneous melanoma: Most of the treatment strategies for chemotherapy have been extrapolated from cutaneous melanoma treatment, however with newer targeted systemic therapy including better understanding of the disease process with further identification and study at the molecular level (mutations in BRAF or KIT) of MM and advent of targeted immune check point inhibitors it has been estimated that the over-all survival of patients with MM should improve.